Evidence map›Paper›PMID 42782889›Full record

Observational studyCurrent oncology (Toronto, Ont.)2026

Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.

Samad Sayed, Rishikesh Kumar, Martin Zarba, Md Mahsin, Amina Taleb, Lateefah Alshammari, Simon Mairs, Naveen Basappa, Michael Kolinsky, Meghan Mahoney and 8 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Samad SayedArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.
Rishikesh KumarCross Cancer Institute, University of Alberta, Edmonton, AB T6G1Z2, Canada.
Martin ZarbaArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.ORCID 0000-0003-3642-4035
Md MahsinArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.
Amina TalebJack Ady Cancer Centre, Alberta Health Services, Lethbridge, AB T1J1W5, Canada.
Lateefah AlshammariArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.ORCID 0000-0002-4565-6092
Simon MairsAlberta Health Services, Red Deer, AB T4N4E7, Canada.
Naveen BasappaCross Cancer Institute, University of Alberta, Edmonton, AB T6G1Z2, Canada.ORCID 0000-0002-3163-9902
Michael KolinskyCross Cancer Institute, University of Alberta, Edmonton, AB T6G1Z2, Canada.
Meghan MahoneyArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.
Vishal NavaniArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.ORCID 0000-0002-6795-009X
Tina ChengArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.
Safiya KarimArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.
Richard Lee-YingArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.ORCID 0000-0003-0913-6046
Steven YipArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.
Daniel Y C HengArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.
Scott NorthCross Cancer Institute, University of Alberta, Edmonton, AB T6G1Z2, Canada.
Nimira AlimohamedArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEnfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC); however, real-world toxicity patterns, timing of onset, and prognostic significance of treatment-related adverse events (AEs) remain incompletely characterized.

methodsWe conducted a retrospective, multicenter analysis of 60 la/mUC patients treated with first-line EVP in Alberta, Canada (September 2024-January 2026). Treatment related toxicities, time to AE onset, dose modifications, and treatment discontinuation were assessed. Progression-free survival (PFS) and overall survival (OS) were analyzed.

resultsThe median age was 69 years, 82% of patients were male, and 80% had metastatic disease at treatment initiation. Histology was pure urothelial in 82% and mixed in 18%. Median follow-up was 10.3 months, and the median number of EV and pembrolizumab cycles was seven and eight, respectively. Rash (63%), fatigue (57%), and peripheral neuropathy (47%) were the most common adverse events, with median onset at 17, 29, and 90 days, respectively. Dose reductions occurred in 62%, dose delays in 43%, and treatment discontinuation in 38%. An initial enfortumab vedotin dose of 1.25 mg/kg was associated with improved PFS (HR 0.30, 95% CI 0.13-0.68;

conclusionsEVP was associated with frequent treatment-related adverse events requiring dose modifications, and the development of rash and peripheral neuropathy was associated with favorable survival outcomes.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalenfortumab vedotinpembrolizumabbiomarkerdose modificationenfortumab vedotinpembrolizumabreal-world evidencetoxicityurothelial carcinoma

Identifiers

PMID42782889
PMCPMC13605319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.